Latest News

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric As...

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Associa

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Associatio...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalat...

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation P

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potentia...

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust...

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targ

Teva Reports First Quarter 2022 Financial Results

Teva Reports First Quarter 2022 Financial Results

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, ...

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims

Research Finds COVID Pandemic Worsened Health Equity Gap

Research Finds COVID Pandemic Worsened Health Equity Gap

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Fina

Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference

Teva Statement Following New York Jury Ruling in Opioids Trial

Teva Statement Following New York Jury Ruling in Opioids Trial

Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Sp...

Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray),

Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide ...

Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0

Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and E

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate...

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and

Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,00...

Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Stateme...

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements A

New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Ti...

New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to

Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes

Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes

Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024

Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024

Teva Reports Third Quarter 2021 Financial Results

Teva Reports Third Quarter 2021 Financial Results

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live w...

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with R

‘Medicine Miles’ Becoming a Concern for European Patients

‘Medicine Miles’ Becoming a Concern for European Patients

Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October...

Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27,

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare...

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disp

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhal...

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Us

Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congre...

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 20

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatme...

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment fo

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be ...

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be prese

Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazi...

Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) T

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion A...

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across

Teva Reports Second Quarter 2021 Financial Results

Teva Reports Second Quarter 2021 Financial Results

Teva Announces Changes to Executive Management Team

Teva Announces Changes to Executive Management Team

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 2...

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 20

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Ja...

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan f